Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

200720062004

2015 Archives

Dec 21, 2015
--Company Expects to Achieve Savings of $40 Million in the First 12 Months, More in Following Years--

Lannett Company, Inc. (NYSE: LCI) today announced that, following a review of its operations including the recently acquired Kremers Urban Pharmaceuticals Inc. (KU), it expects to achieve...

More
Dec 16, 2015
--Company to Discuss Integration Plans--

Lannett Company, Inc. (NYSE: LCI) today announced that it will host a special conference call on Monday, December 21, 2015 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss integration plans....

More
Dec 2, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Oppenheimer 26th Annual Healthcare Conference on Wednesday, December 9, 2015, at 10:20 a.m. ET at the Westin...

More
Nov 27, 2015
- Acquisition creates key player in generic drug industry

Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the U.S. specialty generic pharmaceuticals subsidiary of global...

More
Nov 13, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Jefferies Autumn 2015 Global Healthcare Conference on Wednesday, November 18, 2015, at 10 a.m. GMT. The...

More
Nov 4, 2015
--Net Sales of $106 Million, GAAP EPS OF $0.89, Adjusted EPS of $0.99--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 first quarter ended September 30, 2015. For the fiscal 2016 first quarter, net sales increased to $106.4...

More
Oct 30, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2016 first quarter on Wednesday, November 4, 2015 after the market closes. Lannett management...

More
Oct 28, 2015
--Net Sales of Approximately $106 Million, GAAP EPS of $0.88 to $0.89, Adjusted EPS of $0.98 to $0.99--

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2016 first quarter net sales of approximately $106 million, GAAP earnings per diluted share of $0.88 to $0.89 and...

More
Oct 14, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that its wholly owned subsidiary, Silarx Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) of its...

More
Sep 2, 2015

Transaction Highlights: Substantially increases, diversifies revenue base with highly profitable specialty products Expands pipeline with exciting products Near-term growth potential with 11...

More
Aug 25, 2015
--Company Records Net Sales of $99 Million, EPS of $0.91; Provides Guidance for Fiscal 2016--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 fourth quarter and full year ended June 30, 2015. On June 1, 2015, the company completed the acquisition of...

More
Aug 18, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that its Silarx Pharmaceuticals, Inc. subsidiary has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...

More
Aug 14, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2015 fourth quarter and full year on Tuesday, August 25, 2015 after the market closes....

More
Jul 30, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 35th Annual Growth Conference on Wednesday, August 12, 2015, at 2 p.m. Eastern at the...

More
Jul 9, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors has amended the corporation's bylaws to repeal Article XII in its entirety, effective July 31, 2015. By repealing...

More
Jun 24, 2015

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Albert R. Paonessa, III, to its Board of Directors, effective July 1, 2015. With the addition of Paonessa, the company's Board...

More
Jun 2, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the acquisition of privately held, Silarx Pharmaceuticals, Inc. and a related real estate entity (together "Silarx"), a...

More
May 18, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that it has signed a definitive agreement to acquire privately held, Silarx Pharmaceuticals, Inc. and a related real estate entity (together...

More
May 6, 2015
--Company Records Net Sales of $99 Million, EPS of $0.97; Raises Guidance for Fiscal 2015--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 third quarter ended March 31, 2015. For the fiscal 2015 third quarter, net sales rose 24% to $99.4 million...

More
Apr 30, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2015 third quarter on Wednesday, May 6, 2015 after the market closes. Lannett management will...

More
Apr 24, 2015

Lannett Company, Inc. (NYSE: LCI) today announced that it has amended and increased its five-year revolving credit facility to $120 million from $50 million. The amended facility includes an...

More
Apr 7, 2015

Philadelphia, PA – April 7, 2015 – Lannett Company, Inc. (NYSE: LCI) today announced that the company’s chief executive officer, Arthur Bedrosian, and chief financial officer, Martin...

More
Feb 27, 2015

Philadelphia, PA – February 27, 2015 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 27th Annual ROTH Conference on Monday, March 9, 2015, at...

More
Feb 24, 2015

Philadelphia, PA – February 24, 2015 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the RBC Capital Markets 2015 Healthcare Conference today,...

More
Feb 4, 2015
Company Raises Outlook for Fiscal 2015

Philadelphia, PA – February 4, 2015 – Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 second quarter ended December 31, 2014. For the fiscal 2015...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products